Lupin's Mandideep Unit II facility in Madhya Pradesh receives EIR from USFDA
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh


Representational image. Reuters[/caption]In a filing to BSE, the company said Lupin has received the EIR after closure of the USFDA inspection of its Mandideep Unit II facility, classifying the inspection as "Voluntary Action Indicated."Click here to follow LIVE news and updates on stock markets"We are pleased to have received the EIR for our Mandideep Unit II facility, our important cardiovascular active pharmaceutical ingredients (API) manufacturing facility," Lupin Managing Director Nilesh Gupta said.The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the US, India, South Africa and across Asia Pacific, Latin America, Europe and Middle-East regions.The shares of Lupin Ltd were trading at Rs 851.70 a piece on BSE in morning trade, up 3.12 percent from the previous close.

'From make in India to launch from India': Skyroot COO on why Vikram-1 could change India’s space sector
Google burns cash for first time as AI spending pushes 2026 capex to $205 billion
Tesla sells more cars but makes less money: Why Musk’s AI pivot is squeezing profits
No premium queues, 30-minute target: What changes for Indian passport applicants in UAE
Bharat Forge, Flying Whales sign pact to develop 60-tonne airships for India’s defence logistics

